Stereotaxis Earnings Call: Growth Promise Amid Strains

Stereotaxis ((STXS)) has held its Q4 earnings call. Read on for the main highlights of the call.

Stereotaxis’ latest earnings call mixed clear strategic wins with stubborn execution issues. Management highlighted strong regulatory progress, double‑digit revenue growth and a defined path to higher margins, but also faced questions on catheter shortages, weak system margins and rising cash burn. Investors are being asked to trust that 2025’s groundwork can fuel a more profitable scale‑up in 2026 and beyond.

Regulatory approvals lay groundwork for EP expansion

Stereotaxis secured U.S. and European approvals for its GenesisX robotic system, MAGiC ablation catheter and MAGiC Sweep mapping catheter. These milestones effectively open the door for broader electrophysiology commercialization and position the company for multi‑product adoption as hospitals upgrade both capital systems and disposable toolkits.

Top‑line growth accelerates in 2025

Revenue for 2025 reached $32.4 million, up about 20.5% from $26.9 million in 2024. Fourth‑quarter sales were particularly strong at $8.6 million, a 36% year‑over‑year jump from $6.3 million, underscoring growing demand even as operational bottlenecks persisted.

System revenue rebound driven by GenesisX

System revenue for the full year climbed to $10.2 million from $8.6 million, an increase of roughly 18.6%. In Q4, system revenue surged to $3.3 million from $1.4 million a year earlier, helped by partial revenue recognition on Genesis systems and rising sales of ancillary devices.

Recurring revenue grows despite late‑year setback

Recurring revenue, largely from disposables and services, increased to $22.2 million from $18.3 million, a gain of about 21.3%. This reflected higher catheter volumes and early traction for MAGiC products, suggesting a strengthening consumables base that should be key to long‑term profitability.

Margin profile strong with room to improve

Gross margin came in around 50% for Q4 and about 53% for the full year, with recurring revenue carrying a 67% margin and systems at just 21%. Management outlined a roadmap to push recurring margins above 75% and system margins above 50% within roughly three years as manufacturing capacity expands and fixed overhead is spread over more volume.

Operating discipline gradually narrows losses

Adjusted operating expenses edged down to $26.3 million from $27.0 million, reflecting some cost control despite growth investments. Adjusted operating loss improved to $9.3 million from $12.4 million, and quarterly adjusted operating loss narrowed to $2.6 million from $3.8 million, signaling incremental progress toward breakeven.

Manufacturing ramp targets robots and catheters

Stereotaxis plans to build roughly one GenesisX every two months at its St. Louis facility, with the ability to scale to several dozen systems annually as demand grows. Partner Osypka is expected to ramp MAGiC catheter production to about 500 units per month by year‑end after initial deliveries of just over 100 in March.

Synchrony digital suite builds commercial momentum

The company received a CE Mark for its Synchrony digital suite and has completed FDA interactions, with U.S. clearance expected soon. Management sees early U.S. demand generating more than $3 million in 2026 and envisions a roadmap that adds SynX connectivity and AI‑enabled software features to deepen recurring revenue.

Balance sheet bolstered by fresh equity capital

Stereotaxis ended 2025 with $13.4 million in cash and no debt, providing some cushion for its ramp‑up. The company raised $4.0 million via a registered direct offering and $3.1 million through an at‑the‑market program in Q4 to support ongoing operations and growth investments.

Catheter shortages pressure growth trajectory

Production of MAGiC catheters has lagged targets, with output in the “dozens per month” versus the desired “hundreds per month.” A process change at contract manufacturer Osypka led to catheter shortages in Q4 and early 2026, slowing commercial supply, limiting procedure volumes and weighing on revenue.

Recurring revenue hit by supply and transition

Fourth‑quarter recurring revenue fell sharply to $5.3 million from $9.4 million a year earlier, a decline of about 43.6%. Management attributed the drop primarily to catheter supply constraints and product transition effects, underscoring how sensitive the recurring model is to manufacturing execution.

Cash burn worsens despite operating progress

Negative free cash flow expanded to $13.8 million from $8.5 million, a deterioration of $5.3 million linked mainly to working capital use of about $5.6 million. Investments to support the commercial and manufacturing ramp also contributed, raising the bar for management to deliver on its promised cash‑use improvement in 2026.

System margins constrained by low volume

System gross margin remained weak at roughly 21% for 2025, held back by fixed costs spread over a relatively small production base and low initial yields. As output of GenesisX increases and manufacturing processes mature, the company expects these pressures to ease and system profitability to improve materially.

Losses continue as company scales

Stereotaxis reported a Q4 operating loss of $5.6 million and a net loss of $5.5 million, both better than last year but still firmly negative. Adjusted net loss for 2025 was $8.8 million, highlighting that even with higher revenue and better margins, the platform has not yet reached a self‑funding scale.

New products show modest early revenue impact

Commercial contributions from GenesisX and MAGiC remained relatively small in 2025, with only one GenesisX system sold and MAGiC and MAGiC Sweep each generating only hundreds of thousands of dollars in revenue. Management framed this as an expected gradual start given contracting cycles and manufacturing ramp‑up, with more meaningful impact anticipated in 2026.

China slowdown dampens international outlook

The company cited a sluggish Chinese capital market as a headwind to system placements through its partner MicroPort. Expectations for 2026 are limited to only a handful of Genesis systems in China, reflecting a challenging environment for large capital purchases in that market.

Guidance: 2026 inflection hinges on execution

Management guided 2026 revenue to exceed $40 million, implying continued double‑digit growth with sub‑$10 million quarters in the first half and above‑$10 million quarters in the second half. They plan to establish at least five active GenesisX programs, ramp MAGiC output toward 500 catheters per month, grow Synchrony to more than $3 million in its first full year and improve margins while reducing cash use.

Stereotaxis’ earnings call painted a picture of a company at a pivotal scaling moment, with regulatory wins and product launches setting the stage for higher growth but execution risk still meaningful. For investors, the key question is whether the firm can convert 2025’s approvals and ramps into sustained revenue and margin gains before the balance sheet is stretched too far.